The efficacy of rituximab in patients with neuromyelitis optica spectrum disorder: A real-world study from Turkey

Uzunkopru C., Tutuncu M., Gunduz T., GÜMÜŞ H., Sen S., Demir S., ...More

INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, vol.75, no.7, 2021 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 75 Issue: 7
  • Publication Date: 2021
  • Doi Number: 10.1111/ijcp.14158
  • Journal Name: INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CAB Abstracts, CINAHL, EMBASE, International Pharmaceutical Abstracts, MEDLINE
  • Dokuz Eylül University Affiliated: Yes

Abstract

Background Neuromyelitis optica spectrum disorders (NMOSD) are a group of antibody-mediated chronic inflammatory diseases of the central nervous system. Rituximab is a monoclonal antibody that leads to a reduction in disease activity.